Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 4
1952 1
1956 1
1957 1
1959 6
1960 10
1961 5
1962 5
1963 7
1964 9
1965 10
1971 5
1972 85
1973 229
1974 295
1975 221
1976 129
1977 156
1978 149
1979 144
1980 153
1981 169
1982 176
1983 178
1984 233
1985 177
1986 96
1987 128
1988 181
1989 263
1990 352
1991 929
1992 386
1993 333
1994 310
1995 312
1996 326
1997 338
1998 386
1999 450
2000 488
2001 717
2002 729
2003 964
2004 1041
2005 1103
2006 783
2007 815
2008 786
2009 691
2010 733
2011 779
2012 722
2013 756
2014 739
2015 704
2016 566
2017 543
2018 500
2019 296
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

20,749 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF. Annu Rev Med 2019 - Review. PMID 30691367
The first published description of therapeutic applications of antisense oligonucleotide (ASO) technology occurred in the late 1970s and was followed by the founding of commercial companies focused on developing antisense therapeutics in the late 1980s. Since the late 1980s, there has been steady progress in improving the technology platform, taking advantage of advances in oligonucleotide chemistry and formulations as well as increased understanding of the distribution and safety of ASOs. ...
The first published description of therapeutic applications of antisense oligonucleotide (ASO) technology occurred in the late 1970s …
Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
Schrank Z, et al. Molecules 2018 - Review. PMID 30189661 Free PMC article.
This review aims to provide a comprehensive understanding of current oligonucleotide-based anticancer therapies that target telomeres and telomerase. These studies may help design novel therapeutic approaches to overcome the challenges of oligonucleotide therapy in a clinical setting....
This review aims to provide a comprehensive understanding of current oligonucleotide-based anticancer therapies that target telomeres …
Targeting Huntingtin Expression in Patients with Huntington's Disease
Tabrizi SJ, et al. N Engl J Med 2019 - Clinical Trial. PMID 31059641
IONIS-HTT(Rx) (hereafter, HTT(Rx)) is an antisense oligonucleotide designed to inhibit HTT messenger RNA and thereby reduce concentrations of mutant huntingtin. ...
IONIS-HTT(Rx) (hereafter, HTT(Rx)) is an antisense oligonucleotide designed to inhibit HTT messenger RNA and thereby reduce concentra …
[Therapeutic oligonucleotides: a review].
Wang X, et al. Sheng Wu Gong Cheng Xue Bao 2018 - Review. PMID 29893074 Chinese. Free article.
Therapeutic oligonucleotides include antisense oligonucleotide, small interference RNA (siRNA), Ribozyme, DNAzyme, anti-gene, CpG, decoy and aptamer. ...Comparing with traditional chemical synthesis, PEAR-based enzymatic production of oligonucleotides could be a robust alternative method for the large-scale production of therapeutic or non-therapeutic oligonucleotides....
Therapeutic oligonucleotides include antisense oligonucleotide, small interference RNA (siRNA), Ribozyme, DNAzyme, anti-gene, …
RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43
Mann JR, et al. Neuron 2019. PMID 30826182 Free PMC article.
Furthermore, we show that aberrant phase transitions of cytoplasmic TDP-43 are neurotoxic and that treatment with oligonucleotides composed of TDP-43 target sequences prevent inclusions and rescue neurotoxicity. ...
Furthermore, we show that aberrant phase transitions of cytoplasmic TDP-43 are neurotoxic and that treatment with oligonucleotides co …
Specific inhibition of splicing factor activity by decoy RNA oligonucleotides.
Denichenko P, et al. Nat Commun 2019. PMID 30962446 Free PMC article.
We designed decoy oligonucleotides, composed of several repeats of a RNA motif, which is recognized by a single SF. Here we show that decoy oligonucleotides targeting splicing factors RBFOX1/2, SRSF1 and PTBP1, can specifically bind to their respective SFs and inhibit their splicing and biological activities both in vitro and in vivo. These decoy oligonucleotides present an approach to specifically downregulate SF activity in conditions where SFs are either up-regulated or hyperactive....
We designed decoy oligonucleotides, composed of several repeats of a RNA motif, which is recognized by a single SF. Here we show that …
Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing.
Li B, et al. Cell Rep 2018. PMID 30566855 Free PMC article.
More important, without prehybridization, these PS-modified DNA oligonucleotides showed the ability to suppress DNA double-strand breaks induced by two Cpf1 orthologs, AsCpf1 and LbCpf1. ...Further studies demonstrated that PS-modified DNA oligonucleotides were able to serve as Cpf1 inhibitors in a sequence-independent manner. ...
More important, without prehybridization, these PS-modified DNA oligonucleotides showed the ability to suppress DNA double-strand bre …
20,749 results
Jump to page
Feedback